<p>Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Methotrexate Oral Solution" href="#reference-L7144">4</a></sup> Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Methotrexate Subcutaneous Injection" href="#reference-L7147">5</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Methotrexate Prefilled Syringe for Subcutaneous Injection" href="#reference-L7150">6</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: RediTrex Methotrexate Subcutaneous Injection" href="#reference-L10457">10</a></sup></p><p>Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Methotrexate Injection" href="#reference-L7180">7</a></sup> It is also used in the maintenance of acute lymphocytic leukemia.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Methotrexate Injection" href="#reference-L7180">7</a></sup> Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Methotrexate Injection" href="#reference-L7180">7</a></sup></p>